https://investingnews.com/daily/life-science-investing/genetics-investing/jama-oncology-publication-demonstrates-endopredict-significantly-outperforms-oncotype-dx/
JAMA Oncology Publication Demonstrates EndoPredict Significantly Outperforms Oncotype DX | INN
Jan 5, 2026 - Myriad Genetics (NASDAQ:MYGN) today announced that a comparative analysis of commercially available prognostic breast cancer tests in patients with early-stage...
jama oncologypublicationdemonstratesendopredictsignificantly